Deciphering the genetic evolution of T-cell resistance in melanoma

OncoImmunology

Volumn 4, Issue 5, 2015, Pages

  Sucker, Antje ^a   Paschen, Annette ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

CD8+ T cells; Genetic alterations; HLA class I loss; Melanoma; 2m deficiency

Indexed keywords

BETA 2 MICROGLOBULIN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MELANOMA; T LYMPHOCYTE;

EID: 84944472683     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1005510     Document Type: Article

References (10)

1. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
2. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi. org/10.1038/nature13954
3. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 2005; 102:16013-8.
4. Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103:759-67; PMID:12516095; http:// dx.doi.org/10.1002/ijc.10906
5. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005; 174:1462-71; PMID:15661905; http://dx.doi.org/ 10.4049/jimmunol.174.3.1462
6. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature 2013 Aug 22; 500 (7463):415-21; PMID:23945592; http://dx.doi.org/ 10.1038/nature12477
7. Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maben S, Horn S, Moll I, Maltaner R, Horn PA, et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res 2014; 20:6593-604; PMID:25294904; http://dx.doi.org/ 10.1158/1078-0432.CCR-14-0567
8. Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, et al. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 2006; 12:3297-305; PMID:16740750; http://dx.doi.org/10.1158/1078-0432.CCR-05-2174
9. Maleno I, Aptsiauri N, Cabrera T, Gallego A, Paschen A, López-Nevot MA, Garrido F. Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics 2011 Feb; 63(2):65-71; PMID:21086121; http://dx.doi.org/10.1007/s00251-010-0494-4
10. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer exome analysis reveals a Tcell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx. doi.org/10.1038/nature10755